Mutational spectrum for guiding the decision of adjuvant treatment in patients with resected biliary tract carcinoma
Cancer Medicine · 2023
DOI: 10.1002/cam4.6261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yunfeng Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Carcinoma, Biliary Tract. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Systemic chemotherapy or chemoradiation therapy has proven to be effective in treating advanced biliary tract carcinoma (BTC). However, its efficacy in the adjuvant setting remains controversial. Therefore, this study aimed to determine the prognostic significance of genomic biomarkers in resected BTC and their potential role in stratifying patients for adjuvant treatment.
Methods
We retrospectively reviewed 113 BTC patients who underwent curative‐intent surgery and had available tumor sequencing data. Disease‐free survival (DFS) was the primary outcome examined and univariate analysis was used to identify gene mutations with prognostic value. Favorable and unfavoratble gene subsets were distinguished from the selected genes through grouping, respectively. Multivariate Cox regression was used to identify independent prognostic factors of DFS.
Results
Our results indicated that mutations in ACVR1B , AR , CTNNB1 , ERBB3 , and LRP2 were favorable mutations, while mutations in ARID1A , CDKN2A , FGFR2 , NF1 , NF2 , PBRM1 , PIK3CA , and TGFBR1 were unfavorable mutations. In addition to age, sex, and node positive, favorable genes (HR = 0.15, 95% CI = 0.04–0.48, p = 0.001) and unfavorable genes (HR = 2.86, 95% CI = 1.51–5.29, p = 0.001) were identified as independent prognostic factors for DFS. Out of the 113 patients, only 35 received adjuvant treatment whereas the majority (78) did not. For patients with both favorable and unfavorable mutations undetected, adjuvant treatment showed negative effect on DFS (median DFS: S441 vs. 956 days, p = 0.010), but there was no significant difference in DFS among those in other mutational subgroups.
Conclusions
Genomic testing might be useful in guiding the decisions regarding adjuvant treatment in BTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
- Department of Clinical Medical Laboratory, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
- Shanghai OrigiMed Co., Ltd., Shanghai, China.
ORCID-Profile: Chang-Jun Liu
Zitieren
APA
Li, Y., Tan, C., Yin, X., Zhu, S., Cai, R., Liao, C., Wu, Y., Zeng, Q., Cai, C., Xie, W., He, X., Wen, H. Q., Lin, G., He, Q., He, T., Gu, P., & Liu, C. J. (2023). Mutational spectrum for guiding the decision of adjuvant treatment in patients with resected biliary tract carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.6261
Vancouver
Li Y, Tan C, Yin X, Zhu S, Cai R, Liao C, et al. Mutational spectrum for guiding the decision of adjuvant treatment in patients with resected biliary tract carcinoma. Cancer Medicine. 2023. doi:10.1002/cam4.6261
BibTeX
@article{Li2023,
author = {Li, Yunfeng and Tan, Chaochao and Yin, Xinmin and Zhu, Siwei and Cai, Rongyao and Liao, Chunhong and Wu, Yifei and Zeng, Qihong and Cai, Chengzhi and Xie, Wang and He, Xiangyu and Wen, Hao-Quan and Lin, Guomin and He, Qingqing and He, Tingting and Gu, Peng and Liu, Chang-Jun},
title = {Mutational spectrum for guiding the decision of adjuvant treatment in patients with resected biliary tract carcinoma},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6261}
}
EUVIMED